Debu Tripathy, MD

Articles by Debu Tripathy, MD

Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer

ByJoyce O’Shaughnessy, MD,Virginia Borges, MD,Maryam Lustberg, MD, MPH,Debu Tripathy, MD

January 30th 2023

The panel shares the factors that influence whether they recommend a subcutaneous or intravenous formulation of pertuzumab/trastuzumab in addition to chemotherapy.

De-Escalation Approaches in Patients with HER2+ Early Breast Cancer

ByJoyce O’Shaughnessy, MD,Virginia Borges, MD,Maryam Lustberg, MD, MPH,Debu Tripathy, MD

January 30th 2023

Debu Tripathy, MD, details when he utilizes a treatment de-escalation approach in his patients with HER2+ early breast cancer.

Neoadjuvant Treatment of HER2+ Early Breast Cancer

ByJoyce O’Shaughnessy, MD,Virginia Borges, MD,Maryam Lustberg, MD, MPH,Debu Tripathy, MD

January 20th 2023

A review of the standard of care regimens for the preoperative or neoadjuvant treatment of HER2+ early breast cancer.

Incidence and Typical Prognosis of HER2+ Early Breast Cancer

ByJoyce O’Shaughnessy, MD,Virginia Borges, MD,Maryam Lustberg, MD, MPH,Debu Tripathy, MD

January 20th 2023

Virginia Borges, MD, explains how common HER2+ early breast cancer is and the goals of treatment for patients.

Debu Tripathy, MD

Articles by Debu Tripathy, MD

Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer

De-Escalation Approaches in Patients with HER2+ Early Breast Cancer

Neoadjuvant Treatment of HER2+ Early Breast Cancer

Incidence and Typical Prognosis of HER2+ Early Breast Cancer

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies